The ARK2N Knockout SK-HEP-1 Polyclonal Cells product offers a CRISPR/Cas9-edited polyclonal knockout cell population in which the ARK2N gene has been disrupted across a pool of SK-HEP-1 hepatic sinusoidal endothelial cells. This polyclonal knockout product provides a heterogeneous loss-of-function model suitable for studying the uncharacterized ARK2N protein within a liver endothelial context. By employing CRISPR/Cas9-mediated gene disruption, the resulting polyclonal population contains a spectrum of genetic modifications, enabling functional screening and phenotypic characterization without clonal biases.
The SK-HEP-1 cell line was originally derived from the ascitic fluid of a patient diagnosed with liver adenocarcinoma and has been widely adopted as an in vitro model of hepatic sinusoidal endothelium. These cells stably display hallmark endothelial characteristics such as the expression of vascular endothelial cadherin and von Willebrand factor, and they recapitulate key behaviors of liver sinusoidal endothelial cells including angiogenic sprouting, cell adhesion, and migration. Notably, SK-HEP-1 cells are utilized in cancer biology research for dissecting the tumor microenvironment and in liver fibrosis models due to their endothelial phenotype and origin.
ARK2N encodes a largely uncharacterized protein composed of ankyrin repeat domains and a pseudokinase domain, suggesting that it functions as a scaffold or regulatory factor rather than an active enzyme. Current annotations place ARK2N within the integrin-mediated cell adhesion and focal adhesion pathways, where it is predicted to interact with scaffold proteins such as integrin-linked kinase (ILK) and may associate with focal adhesion complex components including integrin ??1 (ITGB1) and vinculin. Although its upstream regulators are not well defined, ARK2N is thought to be modulated by integrin engagement or growth factor signaling. Downstream, ARK2N is hypothesized to influence cytoskeletal remodeling and the expression or localization of cell adhesion molecules, thereby impacting endothelial cell attachment and motility.
Knockout of ARK2N in SK-HEP-1 cells provides a physiologically relevant platform to investigate the gene??s role in hepatic sinusoidal endothelial biology. Given that SK-HEP-1 cells are commonly employed to study liver angiogenesis and endothelial dysfunction in hepatocellular carcinoma and liver fibrosis, ARK2N disruption may reveal critical contributions to angiogenic tube formation, endothelial barrier function, and migration in response to tumor-derived or fibrotic cues. This polyclonal knockout model is especially valuable for exploring how ARK2N integrates signals at focal adhesions to coordinate endothelial behavior in liver disease contexts.
Researchers can employ this ARK2N knockout pool in various assays, including cell adhesion assays on extracellular matrix components, scratch wound or transwell migration assays, and Matrigel tube formation assays for angiogenic capacity. Immunofluorescence staining for focal adhesion markers such as vinculin and paxillin, together with western blot of adhesion signaling proteins, can elucidate ARK2N??s molecular interactions. RNA-seq can identify downstream transcriptional targets. This product is suited for target validation, pseudokinase mechanistic studies, and drug discovery in liver cancer and fibrosis. For more details or to request custom knockout cell panels, please contact Ascent Research.
